
    
      The randomized clinical trial included subjects (n =216) will be randomly divided into
      experimental (n = 162) and control groups (n =54) according to a random number table.
      Patients in the experimental group will receive Huaiqihuang Granule . Patients in the control
      group will receive placebo a placebo-controlled designed is used for this study. To minimize
      the risks, treatment stopping rules and subsequent measures are established for subjects
      whose disease under study become worsening during the study. Subjects receiving placebo
      treatment will switch to investigational drug after Week 24 to reduce the risk of lack of
      efficacy by placebo.

      The primary outcome measures is proportion of patients whose hemorrhage has improved
      (clinical effective rate).
    
  